Abstract 1312: The estrogen receptor β agonists, Liquiritigenin and S-equol, inhibit breast cancer cell proliferation through the activation of tumor-suppressor and other pathways.

Author(s):  
Cathy Samayoa ◽  
Anil Kotha ◽  
Naveen K. Krishnegowda ◽  
Ratna K. Vadlamudi ◽  
Rajeshwar Rao Tekmal
2019 ◽  
Vol 47 (18) ◽  
pp. 9557-9572 ◽  
Author(s):  
Gozde Korkmaz ◽  
Zohar Manber ◽  
Rui Lopes ◽  
Stefan Prekovic ◽  
Karianne Schuurman ◽  
...  

Abstract Estrogen receptor α (ERα) is an enhancer activating transcription factor, a key driver of breast cancer and a main target for cancer therapy. ERα-mediated gene regulation requires proper chromatin-conformation to facilitate interactions between ERα-bound enhancers and their target promoters. A major determinant of chromatin structure is the CCCTC-binding factor (CTCF), that dimerizes and together with cohesin stabilizes chromatin loops and forms the boundaries of topologically associated domains. However, whether CTCF-binding elements (CBEs) are essential for ERα-driven cell proliferation is unknown. To address this question in a global manner, we implemented a CRISPR-based functional genetic screen targeting CBEs located in the vicinity of ERα-bound enhancers. We identified four functional CBEs and demonstrated the role of one of them in inducing chromatin conformation changes in favor of activation of PREX1, a key ERα target gene in breast cancer. Indeed, high PREX1 expression is a bona-fide marker of ERα-dependency in cell lines, and is associated with good outcome after anti-hormonal treatment. Altogether, our data show that distinct CTCF-mediated chromatin structures are required for ERα- driven breast cancer cell proliferation.


Oncotarget ◽  
2017 ◽  
Vol 8 (44) ◽  
pp. 77137-77151 ◽  
Author(s):  
Ting Zhuang ◽  
Sifan Yu ◽  
Lichen Zhang ◽  
Huijie Yang ◽  
Xin Li ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document